Ірина Давиденко

2.6k total citations · 1 hit paper
33 papers, 1.6k citations indexed

About

Ірина Давиденко is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Ірина Давиденко has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 8 papers in Hepatology. Recurrent topics in Ірина Давиденко's work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Ірина Давиденко is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Ірина Давиденко collaborates with scholars based in United States, United Kingdom and Germany. Ірина Давиденко's co-authors include Kelly S. Oliner, Ghassan K. Abou‐Alfa, Philip J. Johnson, Leonard B. Saltz, Thomas W. T. Leung, Jennifer J. Knox, Marinela Capanu, J. Lacava, Bolorsukh Gansukh and Elwyn Loh and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ірина Давиденко

29 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 314 citations Jan B. Vermorken, Ірина Давиденко et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ірина Давиденко United States	16	807	583	432	403	286	33	1.6k
Felix Chu United States	12	632 0.8×	539 0.9×	324 0.8×	588 1.5×	251 0.9×	19	1.7k
Silvia Mezi Italy	15	1.0k 1.3×	416 0.7×	222 0.5×	252 0.6×	292 1.0×	51	1.4k
Veronica Lonati Italy	22	1.3k 1.6×	656 1.1×	134 0.3×	296 0.7×	307 1.1×	42	1.8k
Süleyman Buyukberber Türkiye	21	653 0.8×	473 0.8×	102 0.2×	256 0.6×	141 0.5×	136	1.5k
Feng-Hua Wang China	27	1.4k 1.7×	613 1.1×	103 0.2×	625 1.6×	192 0.7×	56	2.5k
Morena Fasano Italy	20	680 0.8×	535 0.9×	80 0.2×	605 1.5×	132 0.5×	63	1.4k
Wen-Qi Jiang China	27	1.3k 1.6×	390 0.7×	84 0.2×	268 0.7×	804 2.8×	76	2.1k
Hirofumi Yasui Japan	24	1.2k 1.4×	1.5k 2.6×	122 0.3×	250 0.6×	155 0.5×	159	2.4k
Dominique Grunenwald France	28	1.3k 1.6×	2.1k 3.7×	244 0.6×	299 0.7×	172 0.6×	86	3.3k
Pei-Rong Ding China	20	1.2k 1.5×	271 0.5×	69 0.2×	195 0.5×	145 0.5×	45	1.6k

Countries citing papers authored by Ірина Давиденко

Since Specialization

Citations

This map shows the geographic impact of Ірина Давиденко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ірина Давиденко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ірина Давиденко more than expected).

Fields of papers citing papers by Ірина Давиденко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ірина Давиденко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ірина Давиденко. The network helps show where Ірина Давиденко may publish in the future.

Co-authorship network of co-authors of Ірина Давиденко

This figure shows the co-authorship network connecting the top 25 collaborators of Ірина Давиденко. A scholar is included among the top collaborators of Ірина Давиденко based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ірина Давиденко. Ірина Давиденко is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kristeleit, Rebecca, Ірина Давиденко, Vadim Shirinkin, et al.. (2017). A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecologic Oncology. 146(3). 484–490. 78 indexed citations

Oza, Amit M., Frédèric Selle, Ірина Давиденко, et al.. (2016). Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. International Journal of Gynecological Cancer. 27(1). 50–58. 55 indexed citations

Cunningham, David, Niall C. Tebbutt, Ірина Давиденко, et al.. (2015). Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.. Journal of Clinical Oncology. 33(15_suppl). 4000–4000. 120 indexed citations

Blackwell, Kimberly, Vladimir Semiglazov, Ірина Давиденко, et al.. (2015). Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Annals of Oncology. 26(9). 1948–1953. 65 indexed citations

Cutsem, Eric Van, Cathy Eng, Elżbieta Nowara, et al.. (2014). Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research. 20(16). 4240–4250. 92 indexed citations

Propper, David, Ірина Давиденко, John Bridgewater, et al.. (2014). Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Annals of Oncology. 25(7). 1384–1390. 25 indexed citations

Iveson, Timothy, Ross C. Donehower, Ірина Давиденко, et al.. (2014). Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. The Lancet Oncology. 15(9). 1007–1018. 216 indexed citations

Boucher, Éveline, Ірина Давиденко, D. Hadler, Reinhard von Roemeling, & Giuseppe Aprile. (2014). A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy. Annals of Oncology. 25. ii8–ii8. 2 indexed citations

Cunningham, David, S-E. Al-Batran, Ірина Давиденко, et al.. (2014). Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma. Annals of Oncology. 25. iv250–iv250. 8 indexed citations

10.

Tabernero, Josep, Rocio García‐Carbonero, James T. Cassidy, et al.. (2013). Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research. 19(9). 2541–2550. 69 indexed citations

11.

Vermorken, Jan B., Ірина Давиденко, Lisa Licitra, et al.. (2013). Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. The Lancet Oncology. 14(8). 697–710. 314 indexed citations breakdown →

12.

Abou‐Alfa, Ghassan K., Philip J. Johnson, Jennifer J. Knox, et al.. (2013). Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. 12 indexed citations

13.

Cunningham, David, Salah‐Eddin Al‐Batran, Ірина Давиденко, et al.. (2013). RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4153–TPS4153. 17 indexed citations

14.

Stoehlmacher-Williams, Jan, Cristian Villanueva, Paolo Foa, et al.. (2012). Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.. Journal of Clinical Oncology. 30(15_suppl). 5504–5504. 16 indexed citations

15.

Eng, Cathy, Elżbieta Nowara, Anna Świeboda-Sadlej, et al.. (2011). PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology. 22.

16.

Poddubnaya, I V, Mikhail Lichinitser, Л. В. Болотина, et al.. (2011). Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu. SHILAP Revista de lepidopterología. 1 indexed citations

17.

Ikdahl, Tone, Ірина Давиденко, Claudio Bassi, et al.. (2011). A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy.. Journal of Clinical Oncology. 29(15_suppl). TPS144–TPS144. 4 indexed citations

18.

Eng, Cathy, Eric Van Cutsem, Elżbieta Nowara, et al.. (2011). A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.. Journal of Clinical Oncology. 29(15_suppl). 3500–3500. 31 indexed citations

19.

Abou‐Alfa, Ghassan K., Philip J. Johnson, Jennifer J. Knox, et al.. (2010). Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA. 304(19). 2154–2154. 343 indexed citations

20.

Давиденко, Ірина, Eric Winquist, Lisa Licitra, et al.. (2009). 8514 SPECTRUM, a phase III trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab: interim pooled safety analysis. European Journal of Cancer Supplements. 7(2). 474–475.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact